Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sumatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 7/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 13/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR5A | P47898 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | HTR1F | P30939 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sumatriptan SCHEMBL1482 | 1.00 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL183393 | 1.00 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL1421675 | 0.99 | HTR1A (0.98) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL4916383 | 0.99 | HTR1A (0.98) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL1503483 | 0.96 | HTR1A (0.93) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL29657591 | 0.96 | HTR1A (0.93) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL6688549 | 0.94 | HTR1A (0.89) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL6689001 | 0.93 | HTR1A (0.87) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL29355619 | 0.93 | HTR1D (0.87) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL2404748 | 0.92 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| EP-4208233-A1 | DRUG DELIVERY SYSTEMS AND METHODS AND DRUG PRODUCTS | JANSSEN Pharmaceutica NV (BE) | 2023-07-12 | — | — | EP | claimed |
| WO-2022049136-A1 | DRUG DELIVERY SYSTEMS AND METHODS AND DRUG PRODUCTS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-10 | — | — | WO | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | disclosed |
| WO-2025202172-A1 | INTRANASAL ADMINISTRATION OF BDNF FOR TREATMENT OF PRIMARY HEADACHES | DOMPE' FARMACEUTICI S.P.A. (IT) | 2025-10-02 | — | — | WO | disclosed |
| EP-4623926-A1 | INTRANASAL ADMINISTRATION OF BDNF FOR TREATMENT OF PRIMARY HEADACHES | Dompe' Farmaceutici SpA (IT) | 2025-10-01 | — | — | EP | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | disclosed |
| US-20250114351-A1 | 5-HT2C RECEPTOR MODULATING AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE, MENTAL, COGNITIVE AND AUTOIMMUNE CNS DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-04-10 | — | — | US | disclosed |
| US-20250108080-A1 | EXTRACELLULAR VESICLES FROM GENETICALLY-MODIFIED MICROALGAE CONTAINING ENDOGENOUSLY-LOADED CARGO, THEIR PREPARATION, AND USES | AGS THERAPEUTICS SAS (FR) | 2025-04-03 | — | — | US | disclosed |
| US-11465980-B2 | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114773318-A | Delta opioid receptor modulating compounds containing six-membered azaheterocycles, methods of use and preparation thereof | 特维娜有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4017524-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | Standard of Care Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| CN-108025002-B | Delta opioid receptor modulating compounds containing six membered azaheterocycles, methods of use and preparation thereof | 特维娜有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022079307-A1 | COMPOSITIONS AND USES THEREOF | PURPOSEFUL IKE (GR) | 2022-04-21 | — | — | WO | disclosed |
| US-20220105111-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-3344248-B1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022049136-A1 | DRUG DELIVERY SYSTEMS AND METHODS AND DRUG PRODUCTS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | NLN, DCX, CNTN1 | HTR1D 300/4885HTR1B 374/4885HTR1A 465/4885 |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | HTR1D 155/4885HTR1B 292/4885HTR1A 141/4885 |
| US-11465980-B2 | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | HTR1D 41/4885HTR1B 52/4885HTR1A 28/4885 |
| US-20220105111-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | HTR1D 1199/4885HTR1B 605/4885HTR1A 773/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | HTR1D 4383/4885HTR1B 3290/4885HTR1A 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.